Article Text

PDF
009
INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONS
  1. C Pollack1,
  2. J Eikelboom2,
  3. J Weitz2,
  4. P Reilly3,
  5. S Glund3,
  6. R Dubiel3,
  7. J Kreuzer3,
  8. J Stangier3,
  9. B Wang3,
  10. J Gagg4,
  11. P Verhamme5,
  12. R Bernstein6,
  13. M Huisman7,
  14. E Hylek8,
  15. P Kamphuisen9,
  16. J Levy10,
  17. F Selke11,
  18. T Steiner12,
  19. C Kam13
  1. 1Pennsylvania Hospital, Philadelphia, Pennsylvania, US
  2. 2McMaster, Hamilton, Ontario, Canada
  3. 3Boehringer, Ridgefield, Connecticut, US
  4. 4Musgrove, Taunton, UK
  5. 5Leuven University, Leuven, Belgium
  6. 6NW University, Chicago, Illinois, US
  7. 7Leiden University, Leiden, Netherlands
  8. 8Boston University, Boston, Massachusetts, US
  9. 9Groningen University, Groningen, Netherlands
  10. 10Duke University, Durham, North Carolina, US
  11. 11Brown Medical, Rhode Island, New York, US
  12. 12Heidelberg University, Heidelberg, Germany
  13. 13Tuen Mun Hospital, Tuen Mun, Hong kong

    Abstract

    Objectives & Background Dabigatran, an oral thrombin inhibitor, is widely used for stroke prevention in atrial fibrillation. Idarucizumab, a monoclonal antibody fragment directed against dabigatran, demonstrated immediate, complete and sustained reversal of the anticoagulant effect of dabigatran, without procoagulant activity, in animal models and human volunteers. Aims To examine the efficacy and safety of idarucizumab to rapidly reverse the anticoagulation effects of dabigatran in critical clinical situations.

    Methods RE-VERSE AD is an ongoing multinational, open-label, single cohort study with a target size of up to 300 patients. It is designed to study the reversal of dabigatran's anticoagulant effect by 5 g idarucizumab given as two 2.5 g IV bolus infusions, in patients who experience life-threatening or uncontrollable bleeding (Group A) or who require emergency surgery or invasive procedure (Group B). The primary endpoint is the maximum reversal of the anticoagulant effect of dabigatran, based on central laboratory determination of the dilute thrombin time or ecarin clot time up to 4 hours after idarucizumab administration. Drug levels and other measures of dabigatran activity are also determined. Clinical outcomes, including cessation of bleeding, thrombotic events, and other safety measures, are assessed.

    Results In the first 90 patients, idarucizumab normalized clotting tests in at least 90% of patients, an effect evident at the first measurement. There was one thrombotic event within 72 hours of idarucizumab administration in a patient whose anticoagulant therapy had not been restarted.

    Conclusion Idarucizumab is a promising specific reversal agent that rapidly and safely reverses dabigatran's anticoagulant effects within minutes in emergency situations that reflect real world clinical practice.

    • emergency departments

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.